Valuation: Vanda Pharmaceuticals Inc.

Capitalization 281M 267M 248M 220M 398M 23.85B 441M 3.09B 1.14B 9.79B 1.06B 1.03B 42.74B P/E ratio 2024 *
-15.2x
P/E ratio 2025 * 129x
Enterprise value 92.15M 87.7M 81.28M 72.29M 130M 7.82B 145M 1.01B 374M 3.21B 346M 338M 14.01B EV / Sales 2024 *
0.46x
EV / Sales 2025 * 1.27x
Free-Float
96.85%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day-4.67%
1 week-6.42%
Current month-10.78%
1 month-13.95%
3 months-7.73%
6 months-23.16%
Current year+8.89%
More quotes
1 week
4.55
Extreme 4.545
4.95
1 month
4.55
Extreme 4.545
5.55
Current year
3.46
Extreme 3.46
6.75
1 year
3.46
Extreme 3.46
6.75
3 years
3.30
Extreme 3.295
18.00
5 years
3.30
Extreme 3.295
21.86
10 years
3.30
Extreme 3.295
33.44
More quotes
Director TitleAgeSince
Chief Executive Officer 64 30/04/2003
Director of Finance/CFO 40 14/03/2020
Human Resources Officer - 31/07/2019
Manager TitleAgeSince
Director/Board Member 82 30/11/2005
Chairman 64 -
Director/Board Member 72 13/02/2020
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
-4.67%-6.42%+23.19%-70.94%281M
-0.73%+2.76%+31.80%+125.70%122B
-1.61%+3.89%-8.21%+16.32%84.78B
-0.89%-1.39%+38.79%+121.12%37.38B
-3.05%+1.99%+17.32%-54.25%28.97B
-1.71%+13.18%-23.72%-59.01%23.29B
-10.78%-10.58%+5.55%-38.27%22.06B
-0.32%+1.63%-29.57%-38.21%14.67B
-3.91%+1.18%+756.19%+262.50%13.76B
+0.05%+3.58%+9.64%+63.13%13.07B
Average -2.79%+2.11%+82.10%+32.81% 36.03B
Weighted average by Cap. -1.91%+2.66%+41.11%+59.18%
See all sector performances

Financials

2024 *2025 *
Net sales 198M 189M 175M 156M 281M 16.82B 311M 2.18B 804M 6.91B 744M 728M 30.14B 272M 259M 240M 213M 385M 23.06B 427M 2.99B 1.1B 9.47B 1.02B 998M 41.33B
Net income -18.72M -17.82M -16.51M -14.69M -26.51M -1.59B -29.38M -206M -75.9M -652M -70.28M -68.77M -2.85B 4.57M 4.35M 4.03M 3.58M 6.47M 388M 7.17M 50.17M 18.52M 159M 17.15M 16.78M 695M
Net Debt -189M -180M -167M -148M -268M -16.03B -296M -2.07B -766M -6.58B -709M -694M -28.72B 65.1M 61.96M 57.42M 51.07M 92.2M 5.52B 102M 715M 264M 2.27B 244M 239M 9.9B
More financial data * Estimated data
Logo Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).
Employees
203
More about the company
Date Price Change Volume
10/12/24 4.595 $ -4.67% 1,424,944
09/12/24 4.820 $ -0.41% 616,584
06/12/24 4.840 $ +1.26% 659,777
05/12/24 4.780 $ -1.24% 538,068
04/12/24 4.840 $ -1.43% 760,474

Delayed Quote Nasdaq, December 10, 2024 at 08:30 pm

More quotes
Trading Rating
Investor Rating
ESG Refinitiv
C-
surperformance-ratings-light-chart VANDA-PHARMACEUTICALS-INCMore Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
4.820USD
Average target price
10.43USD
Spread / Average Target
+116.34%
Consensus

Quarterly revenue - Rate of surprise